Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)

Phase Distribution

Ph phase_1
1
50%
Ph not_applicable
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

terminated150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_1

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

NCT06916494
terminatednot_applicable

Sulindac and Plant Compounds in Preventing Colon Cancer

NCT00003365

Clinical Trials (2)

Showing 2 of 2 trials
NCT06916494Phase 1

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Recruiting
NCT00003365Not Applicable

Sulindac and Plant Compounds in Preventing Colon Cancer

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
2